FAP, May 10 / PRNewswire-Asianet /-- Taienkang announced that Jiangsu Bochuangyuan Biopharmaceutical Technology Co., Ltd., a subsidiary of the company, recently received an acceptance notice issued by the State Drug Administration, agreeing to accept the application for phase II clinical trial of CKBA ointment for vitiligo submitted by Bochuangyuan.